HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy's announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.
Bessemer Group Inc. raised its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 30.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchan
Dr. Reddy's Laboratories (NYSE: RDY) reported a "resilient performance" in its fiscal third quarter of FY26, with revenue growth and steady profitability despite what management described as product-s
RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Antihistamineeyedrop--Dr. Reddy's launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Str
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
Dr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront
Fisher Asset Management LLC trimmed its position in shares of Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 20.6% during the undefined quarter, according to its most recent 13F filing with the Securitie
American Century Companies Inc. boosted its holdings in Dr. Reddy's Laboratories Ltd (NYSE: RDY) by 14.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange
BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.
Dr. Reddy's Laboratories (NYSE: RDY - Get Free Report) and Bausch Health Cos (NYSE: BHC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two busin
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, wit
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2026 Earnings Call October 24, 2025 10:00 AM EDT Company Participants Richa Periwal - Head of Investor Relations and Analytics Mannam Venkatanarasimham
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE